Nuvectis Announces Upcoming Oral and Poster Presentations at the 2022 American Association for Cancer Research Meeting
March 10, 2022 08:30 ET
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, March 10, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), (“Nuvectis” or the “Company”) a biopharmaceutical company focused on the development of precision medicines for...
Update - Nuvectis Pharma to Participate in a Fireside Chat at the 34th Annual Roth Conference
March 09, 2022 10:12 ET
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, March 09, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the...
Nuvectis Announces Positive Data for NXP900 in Triple Negative Breast Cancer Preclinical Models with an Integrin-Linked Kinase (ILK) Loss
February 22, 2022 08:30 ET
|
Nuvectis Pharma, Inc.
Data Published in Cancer Research, a journal of the American Association for Cancer Research Publication highlights potent activity of NXP900, a differentiated inhibitor of the SRC/YES1 Kinases ...
Nuvectis Pharma Announces Closing of $16,000,000 Upsized Initial Public Offering of Common Stock
February 08, 2022 13:00 ET
|
Nuvectis Pharma, Inc.
New York, NY, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT) (“Nuvectis”), a biopharmaceutical company that focuses on the development of innovative precision medicines for...
Nuvectis Pharma, Inc. Announces Pricing of $16,000,000 Upsized Initial Public Offering of Common Stock
February 04, 2022 09:30 ET
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of innovative precision...
Nuvectis Pharma Initiates Phase 1 Clinical Trial of NXP800
December 31, 2021 08:00 ET
|
Nuvectis Pharma, Inc.
Fort Lee, NJ , Dec. 31, 2021 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the...
Nuvectis Pharma In-Licenses Exclusive Worldwide Rights to a Novel SRC/YES1 Inhibitor (NXP900) from the University of Edinburgh, Scotland
September 14, 2021 08:00 ET
|
Nuvectis Pharma, Inc.
FORT LEE, NJ , Sept. 14, 2021 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc., a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious...
Nuvectis Pharma Raises $15 Million and In-Licenses Exclusive Worldwide Rights to Novel Selective HSF1 Pathway Inhibitor from the CRT Pioneer Fund
August 26, 2021 08:00 ET
|
Nuvectis Pharma, Inc.
Fort Lee, New Jersey, Aug. 26, 2021 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (the “Company” or “Nuvectis”), a biopharmaceutical company focused on the development of innovative precision medicines...